Product Name:(3R)-pyrrolidin-3-ylmethanol

IUPAC Name:[(3R)-pyrrolidin-3-yl]methanol

CAS:110013-18-8
Molecular Formula:C5H11NO
Purity:97%
Catalog Number:CM105706
Molecular Weight:101.15

Packing Unit Available Stock Price($) Quantity
CM105706-5g in stock ȅǫƴ
CM105706-10g in stock ȖŞƃ
CM105706-25g in stock ȯŪǫ
CM105706-100g in stock Ȗƴƥƴ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:110013-18-8
Molecular Formula:C5H11NO
Melting Point:-
Smiles Code:OC[C@H]1CNCC1
Density:
Catalog Number:CM105706
Molecular Weight:101.15
Boiling Point:
MDL No:MFCD09607969
Storage:

Category Infos

Pyrrolidines
Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

Column Infos

Pyrroles
Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.
NX-2127
Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.

Related Products